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Abstract
 
Mutations in the 
 
NF1
 
 tumor suppressor gene cause neurofibromatosis type I (NF1), a disease
characterized by the formation of cutaneous neurofibromas infiltrated with a high density of
degranulating mast cells. A hallmark of cell lines generated from NF1 patients or 
 
Nf1
 
-deficient
mice is their propensity to hyperproliferate. Neurofibromin, the protein encoded by NF1, neg-
 
atively regulates p21
 
ras
 
 activity by accelerating the conversion of Ras-GTP to Ras-GDP. How-
ever, identification of alterations in specific p21
 
ras
 
 effector pathways that control proliferation in
 
NF1-
 
deficient cells is incomplete and critical for understanding disease pathogenesis. Recent
studies have suggested that the proliferative effects of p21
 
ras
 
 may depend on signaling outputs
from the small Rho GTPases, Rac and Rho, but the physiologic importance of these interac-
tions in an animal disease model has not been established. Using a genetic intercross between
 
Nf1
 
 
 
/
 
 
 
 and 
 
Rac2
 
 
 
/
 
 
 
 mice, we now provide genetic evidence to support a biochemical model
where hyperactivation of the extracellular signal–regulated kinase (ERK) via the hematopoi-
etic-specific Rho GTPase, Rac2, directly contributes to the hyperproliferation of 
 
Nf1
 
-deficient
mast cells in vitro and in vivo. Further, we demonstrate that Rac2 functions as mediator of
cross-talk between phosphoinositide 3-kinase (PI-3K) and the classical p21
 
ras
 
-Raf-Mek-ERK
pathway to confer a distinct proliferative advantage to 
 
Nf1
 
 
 
/
 
 
 
 mast cells. Thus, these studies
identify Rac2 as a novel mediator of cross-talk between PI-3K and the p21
 
ras
 
-ERK pathway
which functions to alter the cellular phenotype of a cell lineage involved in the pathologic
complications of a common genetic disease.
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Introduction
 
Mutations in the 
 
NF1 
 
tumor suppressor gene cause neu-
 
rofibromatosis type I (NF1),
 
*
 
 a pandemic, autosomal domi-
nant disorder with an incidence of 1 in 3,000. Neurofibromin,
the protein encoded by 
 
NF1
 
, functions as a GTPase-acti-
vating protein (GAP) for p21
 
ras
 
 by accelerating the conver-
sion of active p21
 
ras
 
-GTP to inactive p21
 
ras
 
-GDP (1, 2).
Cutaneous neurofibromas are slow-growing tumors that
are pathognomonic for NF1, and mast cells have been im-
plicated in the pathogenesis of neurofibroma formation as
well as other cutaneous tumors (3–7). Recently, we have
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Ras and Rac2 Cooperate in Proliferation of 
 
Nf1
 
-deficient Mast Cells
 
shown that 
 
Nf1
 
 
 
/
 
 
 
 mice have increased numbers of perito-
neal mast cells compared with wild-type littermates (8). In
addition, bone marrow–derived mast cells (BMMCs) cul-
tured from 
 
Nf1
 
 
 
/
 
 
 
 mice demonstrate increased prolifera-
tion relative to wild-type cells in response to stem cell fac-
tor (SCF), a known mitogen for mast cells (8). However,
although these studies show that alterations in p21
 
ras
 
 activ-
ity can alter mast cell fates in vitro and in vivo, little is
known about the contribution of specific p21
 
ras
 
 effector
pathways to the hyperproliferation of 
 
Nf1
 
 
 
/
 
 
 
 mast cells or
other 
 
Nf1
 
-deficient cell types.
Although a critical role for p21
 
ras
 
 in controlling cellular
proliferation has been clearly established, recent studies
have focused on identifying specific p21
 
ras
 
 effector path-
ways important for cell cycle progression. Several studies
have suggested that the proliferative effects of p21
 
ras
 
 may
depend on signaling inputs from the small Rho GTPases,
Rac and Rho (9). Like p21
 
ras
 
, the small Rho GTPases exist
in an inactive (GDP-bound) and active (GTP-bound)
conformation, and interact with target proteins in their
GTP-bound state (9). However, although these studies
have implicated cross-talk between p21
 
ras
 
 and the Rho
GTPases in controlling cellular proliferation, the mecha-
nisms underlying these interactions are still relatively
poorly defined (9). In addition, the physiological impor-
tance of signaling mechanisms that link p21
 
ras
 
 and the Rho
GTPases and its contribution to disease pathogenesis have
not been established.
Previous studies have emphasized that loss of neurofibro-
min results in hyperactivation of the classical p21
 
ras
 
-Raf-
Mek-extracellular signal–regulated kinase (ERK) signaling
pathway in 
 
Nf1
 
-deficient cells leading to hyperproliferation
(10, 11). However, the contribution of Rho GTPases to
this signaling cascade and to the 
 
Nf1
 
 cellular phenotype
have not been previously investigated in primary cells and
in an animal disease model. Using
 
 Nf1
 
 
 
/
 
 
 
 mice and BMMCs,
we now provide pharmacologic, genetic, and biochemical
data to support a model where hyperactivation of ERK
mediated through the hematopoietic-specific Rho GTPase,
Rac 2, directly contributes to the hyperproliferation of
 
Nf1
 
-deficient mast cells in vitro and in vivo. In addi-
tion, we demonstrate that ERK activation in response to
SCF in mast cells is dependent on cross-cascade signals
from phosphoinositide 3-kinase (PI-3K) converging on the
p21
 
ras
 
-Raf-Mek-ERK pathway. Importantly, we identify
Rac2 as a novel mediator of cross-talk between these two
pathways and provide evidence that hyperactivation of
Rac2 can cooperate with p21
 
ras
 
 to alter the function of a
cell lineage implicated in the pathogenesis of a common
genetic disease.
 
Materials and Methods
 
Animals. Nf1
 
 
 
/
 
 
 
 mice were obtained from Tyler Jacks at the
Massachusetts Institute of Technology (Cambridge, MA) in a
C57BL/6.129 background and backcrossed for 13 generations
into the C57BL/6J strain. 
 
Rac2
 
 
 
/
 
 
 
 mice were backcrossed into a
C57BL/6J as described previously (12). These studies were con-
 
ducted with a protocol approved by the Indiana University Labo-
ratory Animal Research Center. The 
 
Nf1 
 
and 
 
Rac2
 
 allele were
genotyped as described previously (12–14). Multiple F0 founders
were used to generate the four 
 
Nf1
 
 and 
 
Rac2
 
 genotypes used in
these experiments as outlined. F0: 
 
Nf1
 
 
 
/
 
 
 
; 
 
 
 
/
 
 
 
 
 
 
 
 
 
 
 
/
 
 
 
; 
 
Rac2
 
 
 
/
 
 
 
.
F1: 
 
Nf1
 
 
 
/
 
 
 
; Rac2
 
 
 
/
 
 
 
 
 
 
 
 
 
 
 
/
 
 
 
; 
 
Rac2
 
 
 
/
 
 
 
. F2: 
 
Nf1
 
 
 
/
 
 
 
; Rac2
 
 
 
/
 
 
 
,
 
 
 
/
 
 
 
; 
 
Rac2
 
 
 
/
 
 
 
, Nf1
 
 
 
/
 
 
 
; 
 
 
 
/
 
 
 
, 
 
 
 
/
 
 
 
; 
 
 
 
/
 
 
 
.
 
Bone Marrow Mast Cell Culture and Proliferation Assays.
 
Six to
nine BMMCs from each murine genotype were generated and
used for proliferation and biochemistry assays. All experiments
were conducted using at least three lines from each genotype.
BMMCs were cultured as described previously (15) with minor
modifications and homogeneity of BMMCs was determined by
Giemsa staining. Aliquots of cells were also stained with alcian
blue and safranin to confirm that they were mast cells. Further-
more, FACS
 
®
 
 analysis revealed similar forward and side light scat-
ter characteristics and the same percentage of c-kit
 
  expression in
BMMCs of all murine genotypes (data not shown). Proliferation
assays were performed as described previously (8). BMMCs from
each genotype were deprived of growth factors for 24 h, and 3  
105 cells were plated in 24-well dishes in 1 ml RPMI containing
1% glutamine (BioWhittaker), 1.5% HEPES (BioWhittaker), 2%
penicillin/streptomycin (BioWhittaker), and 25–100 ng/ml re-
combinant murine SCF (rmSCF; PeproTech) or no growth fac-
tors as indicated in a 37 C, 5% CO2, humidified incubator. In
some experiments, LY294002 (Sigma-Aldrich), PD98059 (New
England Biolabs, Inc.), or DMSO (Sigma-Aldrich) was added to
the cultures 15 min to 1 h before addition of rmSCF. After 72 h,
cells were counted using a hemocytometer. Cell viability was de-
termined by a trypan blue exclusion assay. Assays were performed
in triplicate.
For thymidine incorporation assays, BMMCs were deprived of
growth factors for 24 h and 105 cells were plated in 96-well dishes
in 200 ml of RPMI containing 1% glutamine, 10% fetal bovine
serum (Hyclone Laboratories), and 25–100 ng/ml of rmSCF or
no growth factors, as indicated, in a 37 C, 5% CO2, humidified
incubator. Cells were cultured for 48 h, and tritiated thymidine
(New Life Science Products, Inc.) was added to cultures 6 h be-
fore harvest. In some experiments, LY294002, PD98059, or
DMSO was added to the cultures 15 min to 1 h before addition
of rmSCF. Cells were harvested on glass fiber filters (Packard In-
strument Co.) and   emission was measured. Assays were per-
formed in triplicate.
Raf-1, Mek, ERK, Pak1, and Akt In Vitro Kinase Assays. Ac-
tivation of Raf-1, Mek, ERK, Pak1, and Akt kinases was deter-
mined by depriving BMMCs of serum and growth factors for 18–
24 h and followed by stimulation with 10–100 ng/ml rmSCF for
various amounts of time. Cells were washed twice with PBS con-
taining 1 mM sodium orthovanadate and lysed in nonionic lysis
buffer (20 mM Tris/HCl, 137 mM NaCl, 1 mM EGTA, 1% Tri-
ton X-100, 10% glycerol, 1.5 mM MgCl2, and complete protease
inhibitors (Amersham Pharmacia Biotech), as described previ-
ously (16). The protein lysates were equalized for protein con-
centration using the bicinchoninic acid (BCA) assay (Pierce
Chemical Co.), and equal loading of protein in these assays was
confirmed by Western blot. ERK and Pak1 kinase immunopre-
cipitations were carried out with an anti-ERK-2 (C-14) antibody
(Santa Cruz Biotechnology, Inc.) and an anti-Pak1(C-19) anti-
body (Santa Cruz Biotechnology, Inc.), respectively. Raf-1 and
Mek kinase immunoprecipitations were carried out with an anti-
Raf-1 (C-12) antibody (Santa Cruz Biotechnology, Inc.) and an
anti-Mek-1 (C-18) antibody (Santa Cruz Biotechnology, Inc.),
respectively. Akt kinase immunoprecipitations were carried out59 Ingram et al.
with an anti-Akt antibody (Cell Signaling Technology). The ki-
nase immune complex assay was performed as described previ-
ously (16) and the following proteins were used as phosphoryla-
tion substrates: Elk-1 fusion protein (New England Biolabs, Inc.)
for ERK kinase, histone 2B (Roche) for Akt kinase, myelin basic
protein (Sigma-Aldrich) for Pak1 kinase, and recombinant Mek1
fused with GST at the NH2 terminus (Upstate Biotechnology)
for Raf-1 kinase. For Mek, Raf-1, and ERK, kinase reactions
were resolved on 10% Tris-glycine gels (Novex). For Pak1 and
Akt, kinase reactions were resolved on 4–20% gradient Tris-gly-
cine gels (Novex), and transferred to polyvinylidine difluoride
(PVDF) filters. Gels and PVDF filters were dried and subjected to
autoradiography. Densitometry of individual bands was con-
ducted using NIH Image software.
Ras and Rac Activation Assays. BMMCs were deprived of se-
rum and growth factors for 18–24 h and stimulated at various
amounts of time with 10–100 ng/ml rmSCF. Ras and Rac acti-
vation was subsequently determined using Ras and Rac activa-
tion assay kits (Upstate Biotechnology) according to the manu-
facturer’s protocol and as described previously (17).
Immunoprecipitation and Western Blotting. BMMCs were lysed
in nonionic lysis buffer as described previously (16). Cleared ly-
sates were normalized for protein content using the BCA assay
(Pierce Chemical Co.) and proteins were immunoprecipitated
with protein A sepharose beads (Amersham Pharmacia Biotech)
coupled with polyclonal antibodies for Raf-1 and Mek (Santa
Cruz Biotechnology, Inc.). Immunoprecipitates were washed
three times in lysis buffer, resuspended in sample buffer, boiled
for 5 min, subjected to SDS-PAGE, and transferred to nitrocellu-
lose. The membranes were blocked in TBS-Tween containing
5% BSA overnight. Membranes were incubated for 1–3 h at
room temperature with the following antibodies: anti-phospho-
Mek 1/2 (1:1,000; New England Biolabs, Inc.), anti-phospho-
Raf-1 338 (1:5,000; Upstate Biotechnology), anti-phospho-Mek
298 (gift from Dr. M. Marshall), and anti-p21ras (Upstate Bio-
technology). Secondary antibodies used were either anti–rat,
anti–rabbit, or anti–mouse Ig horseradish peroxidase conjugated
(Transduction Laboratories). Proteins were visualized by en-
hanced chemiluminescence (Santa Cruz Biotechnology, Inc.).
Studies In Vivo. Adult Nf1 / ,  / Rac2 / , Nf1 / Rac2 / ,
and wild-type mice received a continuous infusion of various
doses of rmSCF or vehicle (PBS) from microosmotic pumps
(Alzet) placed under the dorsal back skin. Osmotic pumps were
surgically placed under light avertin anesthesia. rmSCF or vehicle
was released over 7 d at a rate of 0.5  l/hour, and osmotic pumps
were surgically removed on day 7 after sacrifice by cervical dislo-
cation. To accurately identify cutaneous sections for quantitating
changes in mast cell numbers in response to rmSCF, the dorsal
skin was stained with a drop of India ink at the point of exit of
rmSCF from the osmotic pump before removal of the pump. 3-cm
sections of skin marked with India ink were removed, fixed in
buffered formalin, and processed in paraffin-embedded sections.
Specimens were stained with hematoxylin and eosin to assess rou-
tine histology and with Giemsa to identify mast cells. Cutaneous
mast cells were quantitated in a blinded fashion by counting 2-mm2
sections in proximity to the India ink stain.
For studies evaluating basal numbers of mast cells in the Nf1
and Rac intercrossed genotypes, 1-cm sections of ears were re-
moved, fixed in buffered formalin, and processed in paraffin-
embedded sections. Specimens were stained with hematoxylin
and eosin to assess routine histology and Giemsa to identify mast
cells. Cutaneous mast cells from four to five mice per experimen-
tal group were quantitated.
Results
Nf1 /  Mast Cells Have Increased p21ras Activity and Hy-
peractivation of Akt after Stimulation with SCF. SCF binding
to its receptor, c-kit, causes a rapid increase in p21ras activ-
ity in primary BMMCs, and neurofibromin functions as a
GAP for p21ras (1, 2, 15). However, it remains unclear
whether heterozygosity of Nf1 alters p21ras activity in pri-
mary cells. To investigate whether heterozygosity at the
Nf1 allele alters p21ras activity in mast cells, Nf1 /  and
wild-type BMMCs were stimulated with SCF and assayed
for changes in active p21ras-GTP levels. After stimulation
of BMMCs, levels of GTP-bound p21ras in cellular lysates
were determined by precipitating the active GTPase with a
GST fusion of the p21ras binding domain of Raf-1 kinase in
an effector pull-down assay. Even though Nf1 /  mast
cells had detectable, but reduced, levels of neurofibromin
as determined by Western blot (data not shown), Nf1 / 
mast cells had higher basal and SCF-stimulated p21ras-GTP
levels compared with wild-type cells (Fig. 1 A). Impor-
tantly, preincubation of both mast cell genotypes with PI-
3K inhibitors, wortmannin or LY294002, did not alter
p21ras activity (data not shown). Thus, these data position
p21ras either in parallel or upstream of PI-3K in mast cells
and demonstrate that heterozygosity at Nf1 alters p21ras ac-
tivity in primary BMMCs.
Direct binding of the activated c-kit receptor tyrosine
kinase to the SH2 domain of the p85  regulatory subunit
of type IA PI-3K is important for kinase activation after
stimulation by its ligand, SCF (15). Importantly, in immor-
talized cell lines p21ras-GTP has previously been shown to
bind to specific p110 catalytic subunits of type IA PI-3K to
augment kinase activity (18–20). To determine the effect of
increased p21ras-GTP levels on PI-3K activity in Nf1 / 
mast cells, we compared the activation of the serine/threo-
nine protein kinase B (PKB), also known as Akt, in Nf1 / 
and wild-type BMMCs after stimulation with SCF. Activa-
tion of Akt is PI-3K dependent and provides a sensitive
measure for PI-3K activity (21). Nf1 /  BMMCs demon-
strated greater basal and SCF-stimulated Akt activity com-
pared with wild-type cells over a range of SCF concentra-
tions from 10 ng/ml (Fig. 1 B) to 100 ng/ml (data not
shown). In addition, inhibitors of PI-3K inhibited Akt ac-
tivity in both mast cell genotypes (Fig. 1 B), confirming
that p21ras contribution to Akt activation is dependent on
activation of PI-3K. Taken together, these data demon-
strate that increased p21ras activity in Nf1 /  BMMCs after
SCF stimulation is biochemically linked to increased acti-
vation of the PI-3K-Akt kinase pathway.
Hyperproliferation of Nf1 /  Mast Cells in Response to SCF
Is Mediated through Cross-Cascade Activation of ERK from
PI-3K. Proliferation of wild-type BMMCs in response to
SCF is dependent on PI-3K activation (15). Although we
have previously shown that Nf1 /  mast cells have in-
creased proliferation in response to SCF, identification of
p21ras effector pathways responsible for this phenotype re-
main unclear. To test whether SCF-induced hyperprolifer-
ation of Nf1 /  BMMCs is mediated through hyperactiva-60 Ras and Rac2 Cooperate in Proliferation of Nf1-deficient Mast Cells
tion of PI-3K, we performed proliferation assays with
Nf1 /  and wild-type BMMCs in the presence or absence
of the PI-3K inhibitor, LY294002. Nf1 /  and wild-type
BMMCs were cultured in 10% fetal calf serum without
growth factors for 24 h before the addition of SCF. Cell
numbers were determined at the time SCF was added (day
0) and after 72 h in culture. Nf1 /  BMMCs showed a
greater proliferative response to SCF compared with wild-
type cells, as observed previously (8), and the proliferation
of both mast cell genotypes was completely inhibited in the
presence of LY294002 (Fig. 2 A). Similar results were ob-
tained when mast cell proliferation was assessed using thy-
midine incorporation assays to measure DNA synthesis
(data not shown). In addition, consistent differences in pro-
liferation were observed between the genotypes over a
range of SCF concentrations (25–100 ng/ml, data not
shown). Thus, increased SCF-induced proliferation of
Nf1 /  mast cells is mediated through hyperactivation of
the p21ras-PI-3K pathway.
While hyperactivation of the p21ras-PI-3K signaling
pathway provides a simple model to account for the phe-
notype of Nf1 /  BMMCs, we next determined which
specific downstream effectors of PI-3K were responsible
for the hyperproliferation of Nf1 /  mast cells. Recent
studies in immortalized cell lines have shown that signals
from PI-3K converge on the p21ras-Raf-Mek-ERK path-
way to activate ERK and promote transcription of genes
that control mitogenesis (22–25). In addition, we have pre-
viously demonstrated that Nf1 /  BMMCs have elevated
ERK activity relative to wild-type cells after stimulation
with SCF which is consistent with hyperactivation of p21ras
(8). To test whether ERK activity contributes to either
wild-type or Nf1 /  BMMC proliferation, we performed
proliferation assays as described previously with both mast
cell genotypes stimulated with SCF or medium alone, in
the presence or absence of the Mek inhibitor, PD98059.
The Mek inhibitor completely blocked ERK activation in
both mast cell genotypes after stimulation with SCF (data
not shown). In multiple independent experiments (n   6),
addition of PD98059 reduced the proliferative response of
wild-type BMMCs by  10–15% and that of Nf1 / 
BMMCs by 40–50% (Fig. 2 A). Importantly, whereas
PD98059 caused a minimal reduction in wild-type mast
cell proliferation, addition of PD98059 reduced the SCF-
induced hyperproliferation of Nf1 /  mast cells to that of
wild-type levels, establishing the importance of hyperacti-
vation of ERK to the Nf1 /  proliferative phenotype (Fig.
2 A). Similar results were obtained when mast cell prolifer-
ation was assessed using thymidine incorporation assays
(data not shown). Thus, these pharmacologic data suggest
that hyperactivation of ERK confers a distinct proliferative
advantage to Nf1 /  BMMCs in response to SCF.
Given that PI-3K inhibitors significantly block the pro-
liferation of both mast cell genotypes and Mek inhibitors
partially inhibit proliferation, we hypothesized that PI-3K
is biochemically linked to ERK activation in BMMCs. To
test this hypothesis, we stimulated both mast cell genotypes
with SCF in the presence or absence of PI-3K inhibitors
and measured ERK activity. Similar to previous studies (8),
Nf1 /  BMMCs demonstrated a greater increase in ERK
activity from baseline compared with wild-type cells (Fig. 2
B). However, ERK activity was completely inhibited in
both genotypes in the presence of PI-3K inhibitors (Fig. 2
Figure 1. Analysis of p21ras activity and Akt kinase activity of Nf1 / 
and wild-type BMMCs stimulated with SCF. (A) p21ras activity in Nf1 / 
and wild-type BMMCs. GTP-bound p21ras levels were determined by in-
cubating cell lysates with Raf-1 p21ras binding domain (RBD) agarose
beads, fractionating immunoprecipitations by SDS-PAGE, and probing
with anti-p21ras antibody. Immunoblots, quantitative densitometry for
p21ras-GTP levels, and Western blots for total p21ras are shown. Data are
representative of five independent experiments. (B) Akt kinase activity in
Nf1 /  and wild-type BMMCs. After preincubation with 100 nM wort-
mannin or DMSO control for 15 min, Akt kinase activity was determined
from Akt immunoprecipitates and an in vitro kinase assay was performed
using histone 2B as a phosphorylation substrate. Autoradiography and
quantitative densitometry of the phosphorylation of histone 2B and
Western blots for total Akt are shown. Data are representative of four in-
dependent experiments. Similar inhibition of Akt kinase was observed in
cells preincubated for 15 min in 25  M of LY294002, a second PI-3K in-
hibitor (data not shown).61 Ingram et al.
B). Thus, these data demonstrate that ERK activation in
mast cells, in response to SCF, is dependent on biochemical
signals generated through PI-3K converging on the p21ras-
Raf-Mek-ERK pathway.
Cross-Cascade Activation of ERK from PI-3K Occurs at the
Level of Mek and Raf-1 Kinase in Nf1 /  and Wild-Type
Mast Cells. In other experimental systems, cross-cascade
activation of ERK from PI-3K occurs at the level of either
Mek or Raf-1 kinase (22–26). To test whether cross-talk
between PI-3K and the p21ras-Raf-Mek-ERK pathway oc-
curs at the level of Mek, we stimulated Nf1 /  and wild-
type BMMCs with SCF in the presence or absence of a PI-
3K inhibitor and measured Mek activity. Nf1 /  BMMCs
demonstrated a greater increase in Mek activity from base-
line compared with wild-type cells, and Mek activity was
inhibited in the presence of PI-3K inhibitors in both mast
cell genotypes (Fig. 3 A).
Since Raf-1 functions as the immediate upstream effec-
tor of Mek by phosphorylating Mek Ser217/221 (27), we
stimulated Nf1 /  and wild-type mast cells with SCF in
the presence or absence of a PI-3K inhibitor and measured
Raf-1 kinase activity and phosphorylation of these residues
by immunoblot. Whereas wild-type BMMCs demon-
strated minimal Raf-1 kinase activation after stimulation
with 10 ng/ml of SCF, Nf1 /  BMMCs had a significant
increase in Raf-1 kinase activity from baseline in multiple
independent experiments (n   5) which was completely
inhibited in the presence of the PI-3K inhibitor (Fig. 3 B).
In addition, Nf1 /  BMMCs had increased phosphoryla-
tion of Mek Ser217/221 which correlates with increased
Raf-1 activity in these cells (Fig. 3 C). Importantly, phos-
phorylation of these residues was also inhibited by a PI-3K
inhibitor in both mast cell genotypes (Fig. 3 C).
Taken together, as PI-3K inhibitors do not alter p21ras
activity (data not shown), these data suggest a biochemical
model where PI-3K activation of ERK occurs at the level
of either Raf-1 alone or at the level of both Raf-1 and Mek
in BMMCs after stimulation with SCF. Importantly, in-
creased Raf-1 and Mek activity observed in Nf1 /  mast
cells is consistent with the hypothesis that the hyperprolif-
erative phenotype of Nf1 /  BMMCs is directly related to
increased cross-talk from PI-3K to the p21ras-Raf-Mek-
ERK pathway.
Heterozygosity of Nf1 Results in Higher Basal and SCF-stim-
ulated Rac and Pak1 Activity in BMMCs. Given the im-
portance of cross-talk between the PI-3K and the p21ras-
Raf-Mek-ERK pathways to the hyperproliferation of
Nf1 /  BMMCs, we performed experiments to identify
proteins responsible for cross-talk between the two path-
ways. Studies in hematopoietic cells have positioned the
small Rho GTPase, Rac, downstream of PI-3K, and some
experiments in immortalized cell lines have suggested that
Rac1 may function as a mediator of cross-talk between PI-
3K and the p21ras-Raf-Mek-ERK pathways (23, 28–32).
Importantly, Rac1 and Rac2 activation have also been
linked to mast cell proliferation but their contribution to
ERK activation in mast cells has not been studied (33, 34).
Given these prior experiments and our current observa-
Figure 2. Effect of heterozygosity of Nf1 on the proliferation and
ERK kinase activity of BMMCs in response to SCF in the presence or
absence of a Mek or PI-3K inhibitor. (A) Effect of a PI-3K or Mek inhib-
itor on the proliferation of Nf1 /  and wild-type BMMCs in response to
SCF. After deprivation of growth factors for 24 h, 3   105 cells/ml were
placed in triplicate in 24-well dishes in RPMI containing 1% glutamine,
10% fetal bovine serum, and 100 ng/ml of SCF in the presence or ab-
sence of either 50  M PD98059 (Mek inhibitor), 10  M LY294002
(PI-3K inhibitor), or DMSO control in a total volume of 1 ml as de-
scribed previously (8). After 72 h, viable cells were counted using a
hemocytometer and expressed as a percentage of input cells. *P   0.01
for  Nf1 /  vs. Nf1 / ;  **P    0.001 for Nf1 /  vs. Nf1 /  with
LY294002 or PD98059; ***P     0.01 for Nf1 /  vs. Nf1 /  with
LY294002 or PD98059 by Student’s paired t test. (B) ERK activity in
Nf1 /  and wild-type BMMCs after stimulation with SCF in the pres-
ence or absence of 100 nM wortmannin or DMSO control. ERK activity
was determined by depriving cells of serum for 18–24 h, followed by
stimulation with 10 ng/ml of SCF for 2 and 5 min. In some experiments,
cells were preincubated for 15 min with 100 nM wortmannin, 25  M
LY294002 (data not shown), or DMSO control before stimulation. Au-
toradiography and quantitative densitometry of the phosphorylation of
Elk-1 fusion protein by ERK kinase from lysates obtained from SCF-
stimulated BMMCs and Western blots for total ERK are shown. Data are
representative of five independent experiments.62 Ras and Rac2 Cooperate in Proliferation of Nf1-deficient Mast Cells
tions, we measured total Rac activity in both mast cell ge-
notypes in response to SCF. After stimulation of BMMCs,
levels of active, GTP-bound Rac in cellular lysates were
determined by precipitating the active GTPase with a GST
fusion of p21 activated kinase in an effector pull-down as-
say. Nf1 /  mast cells had higher basal and SCF-stimulated
Rac-GTP levels compared with wild-type cells, providing
evidence that p21ras is biochemically linked to Rac activa-
tion. (Fig. 4 A).
Pak1 is a well characterized downstream effector of Rac,
and the catalytic activity of Pak1 is regulated in part by
binding of Rac-GTP to the highly conserved NH2 termi-
nus, known as the Cdc42/Rac interactive binding (CRIB)
domain (35, 36). Importantly, Pak1 has been shown to me-
diate cross-talk between PI-3K and the p21ras-Raf-Mek-
ERK pathway in immortalized cell lines by phosphorylat-
ing specific Raf-1 and Mek residues (22, 25). To test
whether heterozygosity of Nf1 also altered Pak1 activity in
BMMCs, we measured Pak1 activity in both mast cell ge-
notypes in response to SCF. Whereas wild-type mast cells
displayed minimal Pak1 activation, Nf1 /  BMMCs had
dramatically increased basal Pak1 activity which increased
modestly after stimulation with SCF, which is consistent
with increased Rac activity (Fig. 4 B). Thus, these studies
suggest that hyperactivation of the Rac and potentially the
Pak1 pathway confer a distinct proliferative advantage to
Nf1 /  BMMCs.
Hyperactivation of Rac2 Directly Contributes to the Hyperpro-
liferation and Increased ERK Activity in Nf1 /  BMMCs in
Response to SCF. Rac2 is a hematopoietic specific Rho
GTPase, and Rac2 /  mice have multiple mast cell defects
secondary to diminished Rac activity (12, 34). Importantly,
other studies have recently positioned different isoforms of
Rac downstream of PI3-K in hematopoietic cells (for a re-
view, see reference 37). To test our hypothesis that hyper-
activation of Rac2 pathway is directly responsible for the
Figure 3. Analysis of Mek and Raf-1 kinase activity and phosphoryla-
tion of Mek 1/2 serine residues 217/221 in Nf1 /  and wild-type BMMCs
after stimulation with SCF in the presence or absence of a PI-3K inhibitor.
(A and B) Mek (A) and Raf-1 (B) activity in Nf1 /  and wild-type mast
cells after stimulation with SCF in the presence or absence of 100 nM
wortmannin or DMSO control. Raf-1 and Mek kinase activities were de-
termined by depriving cells of serum for 18 h, followed by stimulation with
10 ng/ml of SCF for 2 and 5 min. In some experiments, cells were prein-
cubated for 15 min with 25  M LY294002 before stimulation with SCF
(data not shown). Autoradiography and quantitative densitometry of the
phosphorylation of GST-ERK p42 fusion protein by Mek kinase or
phosphorylation of GST-Mek by Raf-1 kinase are shown. Both Mek and
Raf-1 kinase were obtained from lysates of SCF-stimulated BMMCs.
Western blots for total Mek and Raf-1 are shown. (C) Phosphorylation of
Mek Ser217/221 in BMMCs after stimulation with 10 ng/ml of SCF in
the presence or absence of 100 nM wortmannin, 25  M LY294002, or
DMSO control. Mek was immunoprecipitated from cell lysates and im-
mune complexes were fractionated by SDS-PAGE. Immunoblots were
probed with anti-phospho-Mek Ser217/221 antibody. The phosphoryla-
tion levels were determined by densitometric scanning of the immuno-
blots. Western blots for total Mek are shown. Data are representative of
five independent experiments for each assay.63 Ingram et al.
hyperproliferation of Nf1 /  BMMCs and to potentially
identify which Rac protein may be involved in this signal-
ing pathway, we intercrossed Rac2 /  and Nf1 /  mice,
established BMMCs from the four F2 progeny (see Materi-
als and Methods), and performed proliferation, Pak1, and
ERK activity assays. To initially determine whether Pak1
was located downstream of Rac2 in Nf1 /  and wild-type
mast cells, BMMCs harvested from the mice of the four F2
genotypes were stimulated with SCF and Pak1 activity was
measured. Consistent with our initial observations, Nf1 / 
mast cells had higher basal and SCF induced Pak1 activity
compared with wild-type cells (Fig. 5 A). However, Nf1 / 
Rac2 /  and Nf1 / Rac2 /  BMMCs had minimal Pak1
activation at baseline and in response to SCF (Fig. 5 A).
Thus, these studies identify Pak1 as a downstream effector
of Rac2 in both mast cell genotypes.
To assess the role of Rac2 activation on the proliferation
of Nf1 /  mast cells, BMMCs harvested from mice of the
four F2 genotypes were cultured in 10% fetal calf serum
without added growth factors for 24 h before addition of
SCF. Cell numbers were determined at the time SCF was
added (day 0) and after 72 h in culture. As shown previ-
ously (8, 34), Nf1 / Rac2 /  BMMCs showed a greater
proliferative response to SCF after 72 h in culture com-
pared with wild-type cells, whereas Nf1 / Rac2 /  cells
showed a slight decrease in proliferation (Fig. 5 B). How-
ever, Nf1 / Rac2 /  BMMCs had a 40–50% reduction in
proliferation compared with Nf1 / Rac2 /  BMMCs in
response to SCF (Fig. 5 B). Importantly, the proliferative
responses of Nf1 / Rac2 /  BMMCs were similar to wild-
type cells in multiple independent experiments (n   6; Fig.
5 B). Thus, these experiments provide direct genetic evi-
dence that the hyperproliferative phenotype of Nf1 / 
Rac2 /  mast cells is mediated through activation of the
specific Rac2 isoform.
The reduction in proliferation of Nf1 / Rac2 /  BMMCs
relative to Nf1 / Rac2 /  cells was similar to the reduc-
tion in proliferation observed with the addition of a
Mek inhibitor (and subsequent inhibition of ERK activity)
to the cultures of Nf1 / Rac2 /  mast cells. Given the
similar results of these two experiments, we hypothesized
that Rac2 was biochemically linked to ERK activation af-
ter stimulation of mast cells with SCF. To test this hypoth-
esis, we compared ERK activity in the four F2 mast cell
genotypes after stimulation with SCF. Consistent with
prior observations, Nf1 / Rac2 /  mast cells had higher
Figure 4. Effect of heterozygosity of Nf1 on Rac and Pak1 activity af-
ter stimulation with SCF. (A) Rac activity in Nf1 /  and wild-type
BMMCs. GTP-bound Rac levels were determined by incubating cell
lysates with Pak binding domain agarose beads, fractionating by SDS-
PAGE, and probing with anti-Rac antibodies. Immunoblots and quanti-
tative densitometry for Rac-GTP levels and Western blots of total Rac
are shown. (B) Pak1 activity in Nf1 /  and wild-type mast cells after
stimulation with SCF. Pak1 activity was determined after depriving cells
of serum for 18 h, followed by stimulation with SCF for 1 min. Western
blots for total Pak1 are shown. Autoradiography and quantitative densi-
tometry of the phosphorylation of myelin basic protein by Pak1 kinase
from lysates obtained from SCF-stimulated BMMCs are shown. Western
blots for total Pak1 are shown. Data are representative of four indepen-
dent experiments for each assay.64 Ras and Rac2 Cooperate in Proliferation of Nf1-deficient Mast Cells
ERK activity compared with wild-type cells (Fig. 5 C).
However, Nf1 / Rac2 /  BMMCs had a 50% reduction
in ERK activity compared with wild-type cells, providing
genetic evidence that Rac2 is directly linked to ERK acti-
vation (Fig. 5 C). Consistent with the hypothesized role of
hyperactivation of ERK to the proliferative phenotype of
Nf1 / Rac2 /  mast cells, Nf1 / Rac2 /  mast cells had
equivalent levels of ERK activity compared with wild-type
cells in response to SCF (Fig. 5 C). Thus, these data pro-
vide further genetic confirmation that Rac2-mediated hy-
peractivation of ERK directly contributes to the hyperpro-
liferation of Nf1 /  mast cells in response to SCF.
Increased Accumulation of Mast Cells in Nf1 /  Mice in Re-
sponse to Local Cutaneous Administration of SCF Is Mediated
through Rac2 In Vivo. Local cutaneous injection of SCF
into wild-type mice results in a dramatic accumulation of
mast cells at the site of injection (38, 39). Using 5-bromo-
2 -deoxyuridine (Brdu) labeling in vivo, Tsai et al. demon-
strated that accumulation of mast cells in this experimental
model was closely linked to local cellular proliferation (39).
To test whether heterozygosity at Nf1 alters accumulation
of mast cells to SCF in vivo, slow release microosmotic
pumps were filled with a range of concentrations of SCF or
vehicle and placed into the dorsal back skin of either wild-
type or Nf1 /  mice. 7 d after placement, pumps were re-
moved and cutaneous skin biopsies were taken from the
site of pump insertion and stained with Giemsa stain to
identify mast cells (Fig. 6, A and B). Consistent with our in
vitro experiments, Nf1 /  mice demonstrated greater accu-
mulation of mast cells at the site of SCF release compared
with wild-type mice over a wide range of SCF doses (Fig.
6 C). Interestingly, Nf1 /  mice also had a greater percent-
age of degranulating mast cells at this dose (28 vs. 8%) com-
pared with wild-type mice at the site of SCF release.
To investigate whether the increased accumulation of
mast cells in Nf1 /  mice was mediated through Rac2, we
repeated this experiment using the F2 progeny generated
from the Rac2 /  and Nf1 /  genetic intercross. The SCF
dose chosen for these experiments was 2  g/kg/day, as the
greatest difference in mast cell accumulation between wild-
Figure 5. Effect of Rac2 deficiency on the proliferation and
Pak1 and ERK kinase activity of Nf1 /  and wild-type BMMCs.
(A) Pak1 activity in four Nf1 /  and Rac2 /  mast cell genotypes
after stimulation with SCF. Pak1 activity in BMMCs harvested
from the four F2 progeny composed of the following genotypes
( / ;  / , Nf1 / ;  / ,  / ; Rac2 / , Nf1 / ; Rac2 / )
was determined after depriving cells of serum for 18–24 h, fol-
lowed by stimulation with SCF for 2 min. Autoradiography and
quantitative densitometry of the phosphorylation of myelin basic
protein by Pak1 kinase from lysates obtained from SCF-stimulated
BMMCs and Western blots for total Pak1 are shown. (B) Prolifer-
ation of BMMCs harvested from the four F2 progeny in response
to SCF. After deprivation of growth factors for 24 h, 3   105
cells/ml were placed in triplicate in 24-well dishes in RPMI con-
taining 1% glutamine, 10% fetal bovine serum, and 100 ng/ml of
SCF in the presence or absence of either PD98059 (Mek inhibi-
tor), LY294002 (PI-3K inhibitor), or DMSO control in a total
volume of 1 ml as described previously. After 72 h, viable cells
were counted using a hemocytometer and expressed as a percent-
age of input cells. *P   0.01 for  / ;  /  vs. Nf1 / ;  /  **P  
0.01 for Nf1 / ;  /  vs. Nf1 / ; Rac2 /  ***P   0.01 for  / ;  /  vs. Nf1 / ; Rac2 /  by Student’s paired t test. (C) Analysis of ERK activity in
BMMCs stimulated with SCF in the four F2 genotypes. ERK activity was determined by depriving cells of serum for 18–24 h, followed by stimulation
with 10 ng/ml of SCF for 5 min. Autoradiography and quantitative densitometry of the phosphorylation of Elk-1 fusion protein by ERK kinase from ly-
sates obtained from SCF stimulated BMMCs and Western blots for total ERK are shown. Data are representative of five independent experiments.65 Ingram et al.
type and Nf1 /  mice was observed at this dose (Fig. 6 C).
Consistent with our in vitro proliferation results, the accu-
mulation of mast cells in Nf1 / Rac2 /  mice was greatly
reduced compared with Nf1 / Rac2 /  mice (Fig. 6 D).
Importantly, no differences in mast cell accumulation were
observed between wild-type and Nf1 / Rac2 /  mice
(Fig. 6 D). To determine whether loss of Rac2 alters en-
dogenous cutaneous mast cell numbers in Nf1 /  mice,
histologic sections from the ears of the 4 F2 genotypes
were evaluated after giemsa staining (n   4–5 mice/group).
Cutaneous sections from the ear have been found in previ-
ous studies to be a sensitive site to detect genotypic differ-
Figure 6. Effect of  heterozy-
gosity of Nf1 on accumulation of
cutaneous mast cells in response
to local administration of SCF in
vivo. (A and B) Representative
skin biopsy stained for cutaneous
mast cells taken from the site of
SCF administration via a mi-
croosmotic pump on the middor-
sum of (A) wild-type and (B)
Nf1 /  mice. Specimens were
stained with hematoxylin and
eosin to assess routine histology,
and with Giemsa to identify mast
cells. Cutaneous mast cells were
quantitated in a blinded fashion
by counting 2-mm2 sections. A
higher magnification of areas out-
lined in black boxes of the skin
biopsy are shown to illustrate the
Giemsa-positive mast cells. Black
arrows indicate Giemsa-positive
mast cells. (C) Number of cutane-
ous mast cells per mm2 in Nf1 / 
and wild-type mice in response to
local administration of various
concentrations of SCF. Osmotic
pumps loaded with varying con-
centrations of SCF or PBS were
placed subcutaneously in the dor-
sal skin and removed 7 d later.
Specimens were processed for
quantification of mast cells as de-
scribed in A and B. *P   0.001
for Nf1 /  vs. Nf1 / . (D) Num-
ber of cutaneous mast cell per
mm2 in the four Nf1 and Rac2
genotypes. Osmotic pumps were
loaded with 2  g/kg/day of SCF
or PBS, placed subcutaneously in
the dorsal skin, and removed 7 d
later. Specimens were processed
for quantification as described
above.  *P    0.001 for Nf1 / ;
 /  vs. Nf1 / ;  Rac2 /  by
Student’s paired t test.66 Ras and Rac2 Cooperate in Proliferation of Nf1-deficient Mast Cells
ences in mast cell numbers (40). Interestingly, mice that
were doubly mutant at Nf1 and Rac2 had significantly
lower numbers of mast cells in the ear compared with mice
that were heterozygous at Nf1 alone (Table 1). Thus, cu-
mulatively these studies demonstrate that the biochemical
mechanisms identified in vitro for the Nf1 / Rac2 /  mast
cell phenotype are operative in a more physiologic experi-
mental system.
Discussion
Although p21ras signaling outputs were originally de-
scribed as operating in parallel with activation of PI-3K
pathways, recent studies have suggested that receptor ty-
rosine kinase–mediated activation of ERK is potentially PI-
3K dependent (9, 37). However, the majority of these
studies were conducted in immortalized cell lines, and a
clear example of the physiolgic relevance of cross-talk be-
tween the p21ras-ERK and PI-3K pathways in an animal
disease model has not been established previously. Multiple
lineages of neurofibromin-deficient cells have a propensity
to hyperproliferate in response to various growth factors
which directly relates to the wide diversity of clinical man-
ifestations observed in NF1 (41). Although neurofibromin
has been shown to function as a GAP for p21ras to control
cellular proliferation, lack of identification of alterations in
specific p21ras effectors which control mitogenesis has lim-
ited our understanding of disease pathogenesis. In these ex-
periments, we show that the hyperproliferation of Nf1 / 
mast cells is directly related to increased cross-talk between
the PI-3K and the p21ras-Raf–ERK pathway and identify
Rac2 as a principal mediator of this aberrant signaling path-
way (Fig. 7).
Numerous studies have shown that active p21ras-GTP
can bind to multiple isoforms of the p110 catalytic subunits
of type IA PI-3K to specifically augment kinase activity
(18–20). However, in neurofibromin-deficient cells, most
attention has been focused on modulation of the classical
p21ras-Raf-Mek-ERK pathway to augment cellular prolif-
eration. In primary mast cells, activation of PI-3K after
c-kit binding to SCF is critical for controlling proliferation
(15, 33). Our study shows that Nf1 /  mast cells have a
twofold increase in proliferation in response to SCF com-
pared with wild-type cells, and proliferation was com-
pletely reduced with PI-3K inhibitors, confirming the im-
portance of PI-3K activation to the Nf1 /  cellular
phenotype. Importantly, placement of cutaneous microos-
motic pumps which released a continuous infusion of SCF
resulted in a greater accumulation of mast cells at the site of
insertion in Nf1 /  mice compared with wild-type mice.
Others have previously shown that in vivo mast cell expan-
sion in response to local injection of SCF occurs secondary
to local proliferation (38, 39). Thus, our in vivo observa-
tions argue that the biochemical mechanisms identified in
vitro for the Nf1 /  cell phenotype are valid and biologi-
cally operative in a more physiologic system. As Nf1 / 
mast cells have increased p21ras activity in response to SCF
and a PI-3K inhibitor completely blocks proliferation,
these cell biology studies argue that hyperactivation of the
p21ras-PI-3K pathway in Nf1 /  mast cells altered mast cell
proliferation in vivo and in vitro.
While hyperactivation of PI-3K provides a simple model
for the increased proliferation of Nf1 /  mast cells, we pro-
vide several lines of pharmacologic, genetic, and biochemi-
cal data to demonstrate that hyperactivation of the Rac2-
ERK signaling pathway is directly responsible for the Nf1 / 
cellular phenotype. First, we have previously reported that
Nf1 /  mast cells display increased ERK activation com-
pared with wild-type mast cells after stimulation with SCF,
which is consistent with hyperactivation of p21ras (8).
However, we unexpectedly found that activation of ERK
is dependent on signals from PI-3K and that hyperactiva-
tion of ERK was directly linked to the proliferative pheno-
type of Nf1 /  mast cells. PI-3K inhibitors completely
blocked the activation of ERK in both mast cell genotypes.
The physiological relevance of cross-talk between PI-3K
and the p21ras-Raf-Mek-ERK pathway in Nf1 /  cells is
supported by the effect of a specific Mek inhibitor on the
Table I. Effects of Nf1 and Rac2 Genotypes on Cutaneous Mast 
Cell Numbers
Genotype Number of mast cells per mm2
 / ;  /  69   4.43
Nf1 / ;  /  98   10.32a
 / ; Rac2 /  63   2.94b
Nf1 / ; Rac2 /  63   4.96b
Numbers of cutaneous mast cells were quantitated from ear biopsies.
Results represent mean numbers of mast cells   SEM from five animals
in each genotype.
aP   .053 for comparison of Nf1+/ ;  /  vs.  / ;  / .
bP   .01 for comparison of Nf1+/ ;  /  vs.  / ; Rac2 /  and
Nf1+/ ; Rac2 /  by Student’s t test.
Figure 7. Schematic representation of the hypothesized biochemical
pathway responsible for the hyperproliferative phenotype of Nf1 /  mast
cells in response to SCF. Hatched arrows represent potential downstream
effectors of Rac2.67 Ingram et al.
SCF-stimulated proliferation of these cells. A Mek inhibi-
tor reduces the proliferation of  wild-type cells modestly
(10–15%) in our studies. However, preincubation of Nf1 / 
mast cells with a Mek inhibitor reduces proliferation much
more significantly (40–50%), and importantly, diminishes
the proliferative response to wild-type levels. Thus, in con-
trast to wild-type cells, hyperactivation of ERK from PI-
3K provides a unique signal to confer a distinct proliferative
advantage to Nf1 /  cells.
One interesting observation from these studies is that
constitutive activation of multiple upstream effectors of
ERK including p21ras and Rac does not consistently lead to
constitutive activation of ERK. One potential explanation
for this observation is that mitogen-activated protein kinase
phosphatase (MKP), a phosphatase that specifically binds
and dephosphorylates ERK, may be elevated in Nf1 / 
cells (42, 43). Recently, Brondello et al. have argued that
activation of ERK regulates MKP-1 protein expression
through both an increase in the rate of transcription and in
the rate of proteasome-mediated degradation of MKP-1
(42, 43). Further, these authors argue that upregulation of
MKP-1 in response to activation of ERK may provide an
important negative feedback mechanism to limit inappro-
priate or constitutive activation of ERK. Given the impor-
tance of ERK activity in regulating proliferation and po-
tentially other functions in Nf1 /  mast cells, investigation
of the basal activity of this phosphatase could be important
in future studies. In addition, the regulation of ERK activ-
ity in vivo is likely to be far more complex. It also remains
possible that constitutive activation of upstream effectors of
ERK may circumvent normal feedback mechanisms and
provide a subthreshold level for activation of signaling
pathways necessary for proliferation. In this context, it is
intriguing to note that administration of low dosages (2
 g/kg/day) of exogenous recombinant SCF to Nf1 / 
mice results in profound increases in mast cell numbers
while having no significant effect on wild-type controls.
Next, given the importance of the hyperactivation of
ERK to the proliferative phenotype of Nf1 /  mast cells,
we focused on identifying potential mediators of cross-talk
between the PI-3K and p21ras-Raf-Mek-ERK pathways.
Recent studies have suggested that the proliferative effects
of p21ras are modulated at least in part through signaling in-
puts from the small Rho GTPase, Rac (9). p21-activated
kinase1 (Pak1) has emerged as a molecule that can link
p21ras and Rac signaling by converging on the p21ras-Raf-
Mek-ERK pathway (22, 23, 25). ERK activation has been
linked to the induction of cyclin D1 expression and pro-
gression through G1 of the cell cycle (44, 45). Using a ge-
netic intercross, we show that disruption of the hematopoi-
etic-specific Rho GTPase, Rac2, in Nf1 /  mast cells
restores the proliferative response and ERK activation of
these cells to wild-type levels. Prior studies have shown
that Rac1 activation of c-Jun NH2-terminal kinase (JNK)
is critical for mast cell proliferation (33). However, these
studies used Rac1 dominant negative constructs to trans-
duce primary-derived mast cells, and recent data suggest
that dominant negative Rac1 proteins can potentially in-
hibit different Rac proteins including Rac2 (46). Our ge-
netic data demonstrate that hyperactivation of the specific
Rac2 protein alters the proliferation of Nf1 /  mast cells,
and provides the first evidence in primary cells that p21ras
and Rac2 are biochemically linked. Further, while hyper-
activation of Rac2 may enhance cyclin D1 expression
through increased ERK activation to promote prolifera-
tion, it is possible that Rac2 could also increase cyclin D1
accumulation through an ERK-independent mechanism.
Alternatively, it is also possible that hyperactivation of the
Rac2-ERK pathways promotes proliferation through a sig-
nificantly different mechanism such as the transcription of
genes which control autocrine production of growth fac-
tors. Though our studies cannot definitively discriminate
between these possibilities, it is clear that hyperactivation of
p21ras and Rac2 cooperate to alter the proliferation of neu-
rofibromin-deficient mast cells in vitro and in vivo. Studies
in Nf1-deficient cells are currently underway to evaluate
how p21ras and Rac2 coordinate signals necessary for con-
trolling cell cycle entry and progression and for measuring
release of autocrine growth factors.
Using immortalized cell lines, Pak1 has been shown to
increase signaling through ERK activation by phosphory-
lating specific residues on Raf-1 and Mek (22, 24, 25).
Specifically, activated Pak1 can phosphorylate Mek1 at
Ser298 to enhance the stable association between Raf-1
and Mek1 (22), and Pak1 can also phosphorylate Ser338 in
the Raf-1 catalytic domain to enhance Raf-1 kinase activ-
ity (25). In these prior studies the net effect of increased ac-
tivation of Mek and Raf-1 by Pak1 was increased ERK ac-
tivation in response to different stimuli. Our data suggest
that similar pathways are hyperactive in Nf1-deficient mast
cells and function to increase ERK activity and prolifera-
tion in these cells. Pak1 activity and phosphorylation levels
of Ser338 on Raf-1 and Ser298 on Mek1 (data not shown)
in response to SCF stimulation were greatly increased in
Nf1 /  mast cells compared with wild-type cells. Though
our studies cannot eliminate the possibility that other effec-
tors may contribute to cross-talk between PI-3K and the
p21ras-Raf-Mek-ERK pathway, our data strongly suggest
that hyperactivation of the Rac2 pathway directly accounts
for the hyperproliferation of mast cells (Fig. 7). The ele-
vated levels of Pak1 activity, as well as studies where ex-
pression of a dominant negative Pak1 cDNA reduced ERK
activity in Nf1 /  mast cells to wild-type levels (unpub-
lished results), suggest that Pak1 may serve as the effector
molecule of Rac2 to enhance ERK activity in Nf1 /  mast
cells. These findings are especially intriguing, as placement
of a dominant negative Pak1 or a dominant negative Rac1
has been shown to reverse the transformation of a neurofi-
brosarcoma cell line taken from an individual with NF1
(28). However, as dominant negative constructs may po-
tentially bind other upstream effectors of Pak1, future stud-
ies using Pak1 knockout mice will allow direct testing of
this hypothesis. Given that different isoforms of Rac and
Pak alter the biology of different neurofibromin-deficient
cell lineages, further characterization of these pathways in
Nf1 /  and Nf1 /  primary cells could provide insight into68 Ras and Rac2 Cooperate in Proliferation of Nf1-deficient Mast Cells
the early events leading to loss of heterozygosity and the
subsequent malignant manifestations in NF1.
In summary, recent studies have emphasized an increas-
ing appreciation of the complexity of interactions between
signaling pathways which control specific cellular re-
sponses. Our data provide a clear example in an animal dis-
ease model of how aberrant signaling between two major
pathways can specifically alter the phenotype of a cell lin-
eage implicated in the pathogenesis of a common genetic
disease. Further characterization of this pathway and identi-
fication of similar signaling mechanisms in other neurofi-
bromin-deficient cells should provide biochemical insight
into the complex pathogenesis of NF1.
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